DA1, a peptide that competitively binds to DRP1, can selectively disrupt ATAD3A–DRP1 interaction and eventually suppress mitochondrial fragmentation and mtDNA lesion; notably, this peptide has been used in Huntington’s disease mouse- and patient-derived cells to reduce bioenergetic deficits and cell death [12]. This evidence concerns the gene DNM1L and Huntington disease.